There are 2789 resources available
746P - Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France
Presenter: Manuel Rodrigues
Session: ePoster Display
747P - Real-world experience of rucaparib in patients with ovarian cancer: A multicentre United Kingdom study
Presenter: Mark Lythgoe
Session: ePoster Display
748P - Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)
Presenter: Margarita Romeo Marin
Session: ePoster Display
749P - Cardiotoxicity in patients treated with PARP-inhibitors
Presenter: Mariola Blanco Clemente
Session: ePoster Display
750P - Safety and efficacy of platinum desensitization treatment in patients with ovarian cancer and platinum hypersensitivity
Presenter: Simona Manacorda
Session: ePoster Display
751P - Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group
Presenter: Pauline Corbaux
Session: ePoster Display
752P - PARP-inhibitors beyond progression: A new way to manage oligometastatic ovarian cancer recurrence
Presenter: Eleonora Palluzzi
Session: ePoster Display
753P - Adverse events experienced by patients in the placebo arm of maintenance therapy trials in advanced ovarian cancer
Presenter: Sandy Simon
Session: ePoster Display
614P - Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance
Presenter: J.S. de Bono
Session: ePoster Display
615P - Circulating tumor cells (CTC) gene expression and plasma androgen receptor (AR) copy number (CN) in cabazitaxel-treated metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Giorgia Gurioli
Session: ePoster Display